undamentalytics Newsletter
Sign in

Ocular Therapeutix, Inc balance sheet

At the end of fiscal 2025, Ocular Therapeutix, Inc had total assets of $808m, total liabilities of $154m and shareholders' equity of $654m. It held $737m in cash against $71.3m of debt: net cash of $666m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents24373133425454228164102196392737599
Receivables—00000312212126323130
Inventory—0000011122344
Total current assets—7610770435660246191130232441782644
Total assets—7811075557379262205149252458808671
Accounts payable—1224333554447
Deferred revenue (current)—00——————100——
Total current liabilities—6581391227263135415149
Long-term debt—14151412252517252566697173
Total debt015151618252533262966697173
Total liabilities—192123293782186117114161143154151
Shareholders' equity−475990522636−476883591315654520
Net debt (negative = net cash)−24−23−16−17−24−29−29−195−138−74−130−324−666−526
Shares outstanding——25m25m30m42m50m—77m77m—158m216m220m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: GOSS vs OCULOCUL vs SIGAOCUL vs TNGXEDIT vs OCUL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ocular Therapeutix, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ocular Therapeutix, Inc.